Why have so few proteomic biomarkers "survived" validation? (Sample size and independent validation considerations).
about
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerCurrent strategies and findings in clinically relevant post-translational modification-specific proteomicsLoss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.Multimarker proteomic profiling for the prediction of cardiovascular mortality in patients with chronic heart failureCancer biomarker discovery and validation.COPD Exacerbation Biomarkers Validated Using Multiple Reaction Monitoring Mass Spectrometry.Getting the right answers: understanding metabolomics challenges.Human proteoforms as new targets for clinical mass spectrometry protein tests.A Highly Automated Shotgun Proteomic Workflow: Clinical Scale and Robustness for Biomarker Discovery in Blood.Mass spectrometry protein tests: ready for prime time (or not).Developing clinically relevant biomarkers in inflammatory arthritis: A multiplatform approach for serum candidate protein discovery.Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application.Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer.Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis.Advances in quadrupole and time-of-flight mass spectrometry for peptide MRM based translational research analysis.
P2860
Q26738703-8CE367C3-0953-4731-BE10-8D28F12C36BDQ28085402-A69937FA-90CC-400F-BF18-808D031E95A6Q35045711-B4DD53E8-4412-43D4-BA96-EE491DD3121DQ35532994-3600F410-A2B3-4913-84C1-DDCD1F339501Q35879887-8F425E34-285A-415E-ACB3-C4C7AE72BF17Q36104051-65436769-CC49-4B0E-BD6A-2250DFBCEF32Q38263691-4FB5F817-64E3-49D5-890C-684AE6743B8AQ38649742-358D3BD0-65BE-4611-873E-B8A03873DF7BQ38694919-C21D30DE-ED64-40D9-A14F-C1E95A8F1FE8Q38799731-5364EEEA-A97D-4F80-A8DE-7AFA65469151Q40581625-2C5A3F6C-3E01-48F1-BB91-D0D6BC369E8EQ41173805-50DA24D8-9482-4B44-90E2-673A6013C865Q50675249-399075FE-C950-41A5-AA8A-C04C6303F926Q51043569-E039D872-E392-4751-8BDF-C2E71A2300C8Q53094134-A7151D2E-156D-4D32-89FF-1210AF8A6581
P2860
Why have so few proteomic biomarkers "survived" validation? (Sample size and independent validation considerations).
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Why have so few proteomic biom ...... nt validation considerations).
@en
Why have so few proteomic biomarkers "survived" validation?
@nl
type
label
Why have so few proteomic biom ...... nt validation considerations).
@en
Why have so few proteomic biomarkers "survived" validation?
@nl
prefLabel
Why have so few proteomic biom ...... nt validation considerations).
@en
Why have so few proteomic biomarkers "survived" validation?
@nl
P2860
P356
P1433
P1476
Why have so few proteomic biom ...... nt validation considerations).
@en
P2093
Belinda Hernández
P2860
P304
P356
10.1002/PMIC.201300377
P577
2014-05-16T00:00:00Z